Skip to main content
SpringerLink
Log in

Vaccines for Pandemic Influenza: Summary of Recent Clinical Trials

  • Chapter
  • First Online:
Book cover Vaccines for Pandemic Influenza

Part of the book series: Current Topics in Microbiology and Immunology ((CT MICROBIOLOGY,volume 333))

Abstract

The emergence of influenza A/H5N1 viruses in Asia has raised concerns about their potential to cause pandemic disease. Because vaccination is the primary strategy for the prevention of influenza, efforts are in progress to develop safe and immunogenic vaccines against these viruses and other potential pandemic influenza strains. Results of initial studies indicated that subunit influenza A/H5N1virus vaccines were poorly immunogenic, and that high dosages were needed to induce seroresponses in the majority of subjects. Addition of aluminum-containing adjuvants resulted in variable effects on the immunogenicity of H5 vaccines, but in general, clinically meaningful effects have not been observed. Intradermal immunization was not associated with significant enhancement in one study. More recent studies indicate that oil-in-water adjuvants significantly enhance immune responses when compared with nonadjuvanted preparations containing the same dosage of H5 or H9 hemagglutinin. In addition, these formulations elicit higher levels of cross-reactive antibodies vs. different H5N1 clades. Several whole-virus vaccines have been demonstrated to stimulate high frequencies of responses at relatively low dosages; however, direct comparisons with subunit vaccines have not been made. Finally, candidate live attenuated vaccines are under evaluation in clinical trials. The results of these and future trials will help to identify formulations and immunization regimens for various populations, and will better prepare us to address the threat of both pandemic and interpandemic influenza.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 259.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 329.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 329.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  • Antonovics J, Hood M, Baker C. (2006) Molecular virology: was the 1918 flu avian in origin. Nature 440(7088):E9–E10

    Article  CAS  PubMed  Google Scholar 

  • Atmar RL, Keitel WA, Patel SM, Katz JM, She DW, El Sahly H, Pompey J, Cate TR, Couch RB. (2006) Safety and immunogenicity of nonadjuvanted and MF59-adjuvanted influenza A/H9N2 vaccine preparations. Clin Infect Dis 43:1135–1142

    Article  CAS  PubMed  Google Scholar 

  • Bean WJ, Schell M, Katz J et al. (1992) Evolution of the H3 influenza virus hemagglutinin from human and nonhuman hosts. J Virol 66:1129–1138

    CAS  PubMed  Google Scholar 

  • Belshe RB, Newman FK, Cannon J, Duane C, Treanor J, Van Hoecke C, Howe BJ, Dubin G. (2004) Serum antibody responses after intradermal vaccination against influenza. N Engl J Med 351:2286–2294

    Article  CAS  PubMed  Google Scholar 

  • Belshe RB, Newman FK, Wilkins K, Graham IL, Babusis E, Ewell M, Frey SE. (2007) Comparative immunogenicity of trivalent influenza vaccine administered by intradermal or intramuscular route in healthy adults. Vaccine 25:6755–6763

    Article  CAS  PubMed  Google Scholar 

  • Bernstein D, Edwards K, Dekker C, Belshe R, Talbot H, Graham I, Noah D, He F, Hill H. (2008) Effects of adjuvants on the safety and immunogenicity of an avian influenza H5N1 vaccine in adults. J Infect Dis 197:667–675

    Article  CAS  PubMed  Google Scholar 

  • Brady RC, Treanor JJ, Atmar RL, Chen WH, Winokur P, Belshe R. (2007) A phase I-II, randomized, controlled, dose-ranging study of the safety, reactogenicity, and immunogenicity of intramuscular inactivated influenza A/H5N1 vaccine given alone or with aluminum hydroxide to healthy elderly adults. Abstract P739 of the Options for the Control of Influenza VI Meeting, Toronto, ON, Canada, 17–23 June 2007

    Google Scholar 

  • Bresson JL, Perronne C, Launay O, Gerdil C, Saville M, Wood J, Höschler K, Zambon MC. (2006) Safety and immunogenicity of an inactivated split-virion influenza A/Vietnam/1194/2004 (H5N1) vaccine: phase I randomised trial. Lancet 367:1657–1664

    Article  CAS  PubMed  Google Scholar 

  • Campbell J, Graham I, Zangwill K. (2007) Pediatric H5N1 vaccine trial (online slideshow). http://www.who.int/vaccine_research/diseases/influenza/150207_Campbell.pdf

  • Chen H, Smith GJ, Li KS et al (2006) Establishment of multiple sublineages of H5N1 influenza virus in Asia: implications for pandemic control. Proc Natl Acad Sci USA 103:2845–2850

    Article  CAS  PubMed  Google Scholar 

  • Committee for Human Medicinal Products (CHMP) (2007) Influenza vaccines prepared from viruses with the potential to cause a pandemic and intended for use outside of the core dossier context. CHMP/VWP/263499/06, 1–11

    Google Scholar 

  • Cunha B. (2004) Influenza: historical aspects of epidemics and pandemics. Infect Dis Clin North Am 18(1):141–55

    Article  PubMed  Google Scholar 

  • Desheva JA, Lu XH, Rekstin AR, Rudenko LG, Swayne DE, Cox NJ, Katz JM, Klimov AI. (2006) Characterization of an influenza A H5N2 reassortant as a candidate for live-attenuated and inactivated vaccines against highly pathogenic H5N1 viruses with pandemic potential. Vaccine 24:6859–6866

    Article  CAS  PubMed  Google Scholar 

  • Ehrlich H, Muller M, Oh H, Tambyah P, Joukhadar C, Montomoli E, Fisher D, Berezuk G, Fritsch S, Low-Baselli A, Vartian N, Bobrovsky R, Pavlova B, Pollabauer E, Kistner O, Barrett P (2008) for the Baxter H5N1 pandemic influenza vaccine clinical study team. A clinical trial of a whole-virus H5N1 vaccine derived from cell culture. N Engl J Med 358:24:2573–2584

    Article  CAS  PubMed  Google Scholar 

  • Ernst WA, Kim HJ, Tumpey TM, Jansen ADA, Tai W, Cramer DV, Adler-Moore JP, Fujii G. (2006) Protection against H1, H5, H6 and H9 influenza A infection with liposomal matrix 2 epitope vaccines. Vaccine 24:5158–5168

    Article  CAS  PubMed  Google Scholar 

  • Food and Drug Administration. (2006) Draft guidance for industry on clinical data needed to support the licensure of trivalent inactivated influenza vaccines. Fed Reg 71:12367

    Google Scholar 

  • Gibbs M, Gibbs A. (2006) Molecular virology: was the 1918 pandemic caused by bird flu. Nature 440:27:E8

    Article  CAS  PubMed  Google Scholar 

  • Glezen PW. (1996) Emerging infections: pandemic influenza. Epidemiol Rev 18:64–76

    CAS  PubMed  Google Scholar 

  • Goji N, Nolan C, Hill H, Wolff M, Noah D, Williams T, Rowe T, Treanor J. (2008) Immune responses of healthy subjects to a single dose of intramuscular inactivated influenza A/Vietnam/1203/2004 (H5N1) vaccine after priming with an antigenic variant. J Infect Dis 198:9: 635–641

    Article  PubMed  Google Scholar 

  • Govorkova EA, Webby R, Humberd J, Seiler JP, Webster RG. (2006) Immunization with reverse-genetics-produced H5N1 influenza vaccine protects ferrets against homologous and heterologous challenge. J Infect Dis 194:159–167

    Article  CAS  PubMed  Google Scholar 

  • Guan Y, Poon LL, Cheung CY et al. (2004) H5N1 influenza: a protean pandemic threat. Proc Natl Acad Sci USA 101, 8156–8161

    Article  CAS  PubMed  Google Scholar 

  • Hampson A. (2006) Ferrets and the challenges of H5N1 vaccine formulation. J Infect Dis 194:143–145

    Article  PubMed  Google Scholar 

  • Hanson BJ, Boon ACM, Lim APC, Webb A, Ooi EE, Webby RJ. (2006) Passive immunoprophylaxis and therapy with humanized monoclonal antibody specific for influenza A H5 hemagglutinin in mice. Respir Res 7:126

    Article  PubMed  Google Scholar 

  • Hehme N, Engelmann H, Kunzel W, Neumeier, Sanger R. (2002) Pandemic preparedness: lessons learnt from H2N2 and H9N2 candidate vaccines. Med Microbiol Immunol 191:203–208

    Article  CAS  PubMed  Google Scholar 

  • Hehme N, Engelmann H, Kuenzel W, Neumeier E, Saenger R. (2004) Immunogenicity of a monovalent, aluminum-adjuvanted influenza whole virus vaccine for pandemic use. Virus Res 103:16–171

    Article  Google Scholar 

  • Hoelscher MA, Garg S, Bangari DS et al (2006) Development of adenoviral-vector-based pandemic influenza vaccine against antigenically distinct human H5N1 strains in mice. Lancet 367:475–481

    Article  CAS  PubMed  Google Scholar 

  • Karron R, Callahan K, Luke C et al. (2007) Phase I evaluation of live attenuated H9N2 and H5N1 ca reassortant vaccines in healthy adults (online slideshow). http://www.who.int/vaccine_research/diseases/influenza/160207_Karron.pdf

  • Karron R et al. (2008) Clinical evaluation of live attentuated pandemic influenza virus vaccines (online slideshow). http://www.who.int/vaccine_research/diseases/influenza/Karron_infleunza_meeting_140208.pdf

  • Karron RA, Callahan K, Luke C, Thumar B, McAuliffe J, Schappell E, Joseph T, Coelingh K, Jin H, Kemble G, Murphy BR, Subbarao K. (2009) A live attenuated H9N2 influenza vaccine is well tolerated and immunogenic in healthy adults. J Infect Dis 199:711–16

    Article  PubMed  Google Scholar 

  • Keitel W, Campbell J, Treanor J, Walter E, Patel S, He F, Noah D, Hill H. (2008) Safety and immunogenicity of an inactivated influenza A/H5N1 vaccine given with or without aluminum hydroxide to healthy adults: Results of a phase-I-II randomized clinical trial. J Infect Dis 198:11:1309–1315

    Article  PubMed  Google Scholar 

  • Kenney RT, Frech SA, Muenz LR, Villar CP, Glenn GM. (2004) Dose sparing with intradermal injection of influenza vaccine. N Engl J Med 351:2295–2301

    Article  CAS  PubMed  Google Scholar 

  • Kistner O. (2007) Phase 1/2 clinical study with Baxter’s H5N1 vaccine: clinical update (online slideshow). http://www.who.int/vaccine_research/diseases/influenza/150207_Kistner_Baxter.pdf

  • Kodihalli S, Goto H, Kobasa DL, Krauss S, Kawaoka Y, Webster RG. (1999) DNA vaccine encoding hemagglutinin provides protective immunity against H5N1 influenza virus infection in mice. J Virol 73:2094–2098

    CAS  PubMed  Google Scholar 

  • Koopmans M, Wilbrink B, Conyn M, Natrop G, van der Nat H, Vennema H, Meijer A, van Steenbergen J, Fouchier R, Osterhaus A, Bosman A. (2004) Transmission of H7N7 avian influenza A virus to human beings during a large outbreak in commercial poultry farms in the Netherlands. Lancet 363:587–593

    Article  PubMed  Google Scholar 

  • Krasilnikov I. (2008) MICROGEN’s pandemic vaccine clinical development (online slideshow). http://www.who.int/vaccine_research/diseases/influenza/Krasilnokov_infleunza_meeting_140208.pdf

  • Laddy DJ, Yan J, Corbitt N, Kobasa D, Kobinger GP, Weiner DB. (2007) Immunogenicity of novel consensus-based DNA vaccines against avian influenza. Vaccine 25:2984–2989

    Article  CAS  PubMed  Google Scholar 

  • Levie K, Leroux-Roels I, Hoppenbrouwers K, Kervyn A-D, Vandermeulen C, Forgus S, Leroux-Roels G, Pichon S, Kusters I. (2008) An adjuvanted, low-dose, pandemic influenza A (H5N1) vaccine candidate is safe, immunogenic, and induces cross-reactive immune responses in healthy adults. J Infect Dis 198:9:642-649

    Article  PubMed  Google Scholar 

  • Leroux-Roels, Barkowski A, Vanwolleghem T, Dramé M, Clement F, Hons E, Devaster JM, Leroux-RoelsG. (2007) Antigen sparing and cross-reactive immunity with an adjuvanted rH5N1 prototype pandemic influenza vaccine: a randomized controlled trial. Lancet 370:580–589

    Article  CAS  PubMed  Google Scholar 

  • Leroux-Roels I, Bernhard R, Gérard P, Dramé M, Hanon E, Leroux-Roels G. (2008) Broad clade 2 cross-reactive immunity induced by an adjuvanted clade 1 rH5N1 pandemic influenza vaccine. PLoS One 3(2):e1665

    Article  PubMed  Google Scholar 

  • Lin YP, Shaw M, Gregory V et al. (2000) Avian-to-human transmission of H9N2 subtype influenza A viruses: relationship between H9N2 and H5N1 human isolates. Proc Natl Acad. Sci USA 97:9654–9658

    Article  CAS  PubMed  Google Scholar 

  • Lin J, Zhang J, Dong X, Fang H, Chen J, Su N, Gao Q, Zhang Z, Liu Y, Wang Z, Yang M, Sun R, Li C, Lin S, Ji M, Liu Y, Wang X, Wood J, Feng Z, Wang Y, Yin W. (2006) Safety and immunogenicity of an inactivated adjuvanted whole-virion influenza A (H5N1) vaccine: a phase I randomised controlled trial. Lancet 368, 991–997

    Article  CAS  PubMed  Google Scholar 

  • Lipatov AS, Webby RJ, Govorkova EA, Krauss S, Webster RG. (2005) Efficacy of H5 influenza vaccines produced by reverse genetics in a lethal mouse model. J Infect Dis 191:1216–1220

    Article  CAS  PubMed  Google Scholar 

  • Lipatov AS, Hoffman E, Salomon R, Yen HL, Webster RG. (2006) Cross-protectiveness and immunogenicity of influenza A/Duck/Singapore/3/97(H5) vaccines against infection with A/Vietnam/1203/04(H5N1) virus in ferrets. J Infect Dis 194:1040–1043

    Article  CAS  PubMed  Google Scholar 

  • Lu J, Guo Z, Pan X, Wang G, Zhang D, Li Y, Tan B, Ouyang L, Yu X. (2006a) Passive immunotherapy for influenza A/H5N1 virus infection with equine hyperimmune globulin F (ab′)2 in mice. Respir Res 7:43

    Article  CAS  Google Scholar 

  • Lu X, Edwards LE, Desheva JA, Nguyen DC, Rekstin A, Stephenson I, Szretter K, Cox NJ, Rudenko LG, Klimov A, Katz JM. (2006b) Cross-protective immunity in mice induced by live-attenuated or inactivated vaccines against highly pathogenic influenza A (H5N1) viruses. Vaccine 24:6588–6593

    Article  CAS  Google Scholar 

  • Luke TC, Kilbane EM, Jackson JL, Hoffman SL. (2006) Meta-analysis: convalescent blood products for Spanish influenza pneumonia: a future H5N1 treatment. Ann Intern Med 145:599–609

    PubMed  Google Scholar 

  • Ma W, Vincent A, Gramer M, Brockwell C, Lager K, Janke B, Gauger P, Patnayak D, Webby R, Richt J. (2007) Identification of H2N3 influenza A viruses from swine in the United States. Proc Natl Acad Sci USA 104:52:20949–20954

    Article  CAS  PubMed  Google Scholar 

  • Maassab HF, DeBorde DC. (1985) Development and characterization of cold-adapted viruses for use as live virus vaccines. Vaccine 3:355–69

    Article  CAS  PubMed  Google Scholar 

  • Neumann G, Watanabe T, Ito H, Watanabe S, Goto H, Gao P, Hughes M, Perez DR, Donis R, Hoffmann E, Hobom G, Kawaoka Y. (1999) Generation of influenza A viruses entirely from cloned cDNAs. Proc Natl Acad Sci USA 96:9345–9350

    Article  CAS  PubMed  Google Scholar 

  • Nicholson KG, Colgate AE, Podda A, Stephenson I, Wood J, Ypma E, Zambon MC. (2001) Safety and antigenicity of non-adjuvanted and MF59-adjuvanted influenza A/Duck/Singapore/97 (H5N3): a randomized trial of two potential vaccines against H5N1 influenza. Lancet 357:1937–1943

    Article  CAS  PubMed  Google Scholar 

  • Nolan T, Richmond P, Skeljo M, Pearce G, Hartel G, Formica N, Hoschler K, Bennet J, Ryan D, Papanaoum K, Basser R, Zambon M. (2008a) Phase I and II randomised trials of the safety and immunogenicity of a prototype adjuvanted inactivated split-virus influenza A (H5N1) vaccine in healthy adults. Vaccine 26:4160–4167.

    Article  CAS  Google Scholar 

  • Nolan T, Richmond P, Skeljo M et al.. (2008b) Prototype H5N1 pandemic influenza vaccine: further studies on elderly and children (online slideshow). http://www.who.int/vaccine_research/diseases/influenza/Nolan_infleunza_meeting_140208.pdf

  • Nolan T, Richmond P, Formica N, Hoschler K, Skeljo M, Stoney T, McVernon J, Hartel G, Sawlwin D, Bennet J, Ryan D, Basser R, Zambon M. (2008c) Safety and immunogenicity of a prototype adjuvanted inactivated split-virus influenza A (H5N1) vaccine in infants and children. Vaccine 26:6383–91.

    Article  CAS  Google Scholar 

  • Patel SM, Atmar RL, El Sahly H, Cate TR, Keitel WA. (2006) A randomized, open-label, phase I clinical trial comparing the safety, reactogenicity, and immunogenicity of booster immunization with inactivated influenza A/H5N1 vaccine administered by the intradermal (ID) or the intramuscular (IM) route among healthy adults. In: 44th Annual Meeting of the Infectious Diseases Society of America, Toronto, ON, Canada, 12–15 Oct 2006

    Google Scholar 

  • Patel SM, Atmar RL, El Sahly H, Cate TR, Keitel WA. (2008) A phase I/II, randomized, double-blinded placebo-controlled trial to assess the safety, reactogenicity, and immunogenicity of immunization with inactivated subvirion influenza A/H5N1 vaccine administered by the intradermal or the intramuscular route among healthy adults. Abstract S1 of the 11th Annual Conf on Vaccine Research, Baltimore, MD, 5–7 May 2008

    Google Scholar 

  • Ruat C, Caillet C, Bidaut A, Simon J, Osterhaus A. (2008) Vaccination of macaques with adjuvanted formalin-inactivated influenza A virus (H5N1) vaccines: protection against H5N1 challenge without disease enhancement. J Virol 82:2565–69

    Article  CAS  PubMed  Google Scholar 

  • Rudenko L, Katlinsky A. (2007) Evaluation of Russian live evaluation of Russian live attenuated vaccine H5N2 attenuated vaccine H5N2 in clinical trials (online slideshow). http://www.who.int/vaccine_research/diseases/influenza/160207_Rudenko.pdf

  • Rümke HC, Bayas JM, de Juanes JR, Caso C, Richardus JH, Campins M, Rombo L, Duval X, Romanenko V, Schwarz TF, Fassakhov R, Abad-Santos F, von Sonnenburg F, Dramé M, Sänger R, Ballou WR. (2008) Safety and reactogenicity profile of an adjuvanted H5N1 pandemic candidate vaccine in adults within a phase III safety trial. Vaccine 26(19):2378–2388. doi:10.1016/j.vaccine.2008.02.068

    Article  PubMed  Google Scholar 

  • Shinya K, Ebina M, Yamada S, Ono M, Kasai N, Kawaoka Y. (2006) Influenza virus receptors in the human airway. Nature 440:435–436

    Article  CAS  PubMed  Google Scholar 

  • Stephenson I, Nicholson KG, Colegate A, Podda A, Wood J, Ypma E, Zambon M. (2003a) Boosting immunity to influenza H5N1 with MF59-adjuvanted H5N3 A/Duck/Singapore/97 vaccine in a primed human population. Vaccine 21:1687–1693

    Article  CAS  Google Scholar 

  • Stephenson I, Nicholson KG, Glück R, Mischler R, Newman RW, Palache AM, Verlander NQ, Warburton F, Wood JM, Zambon MC. (2003b) Safety and antigenicity of whole virus and subunit influenza A/Hong Kong/1073/99 (H9N2) vaccine in healthy adults: phase I randomized trial. Lancet 362:1959–1966

    Article  CAS  Google Scholar 

  • Stephenson I, Wood JM, Nicholson KG, Zambon MC. (2003c) Sialic acid receptor specificity on erythrocytes affects detection of antibody to avian influenza haemagglutinin. J Med Virol 70:391–398

    Article  CAS  Google Scholar 

  • Stephenson I, Wood JM, Nicholson KG, Charlett A, Zambon MC. (2004) Detection of anti-H5 responses in human sera by HI using horse erythrocytes following MF59-adjuvanted influenza A/Duck/Singapore/97 vaccine. Virus Res 103:91–95

    Article  CAS  PubMed  Google Scholar 

  • Stephenson I, Bugarini R, Nicholson KG, Podda A, Wood JM, Zambon MC, Katz JM. (2005) Cross-reactivity to highly pathogenic avian influenza H5N1 viruses after vaccination with non-adjuvanted and MF59-adjuvanted influenza A/Duck/Singapore/97 (H5N3) vaccine: a potential priming strategy. J Infect Dis 191:1210–1215

    Article  PubMed  Google Scholar 

  • Stephenson I, Das RG, Wood JM, Katz JM. (2007) Comparison of neutralising antibody assays for detection of antibody to influenza A/H3N2 viruses: an international collaborative study. Vaccine 25:4056

    Article  CAS  PubMed  Google Scholar 

  • Suguitan AL Jr, McAuliffe J, Mills KL, Jin H, Duke G, Lu B, Luke CJ, Murphy B, Swayne DE, Kemble G, Subbarao K. (2006) Live, attenuated influenza A H5N1 candidate vaccines provide broad cross-protection in mice and ferrets. PLoS Med 3:e360

    Article  PubMed  Google Scholar 

  • Tashiro M. (2007) Development of pandemic vaccine in Japan: P I and P II/III clinical studies (online slideshow). http://www.who.int/vaccine_research/diseases/influenza/150207_Tashiro.pdf

  • Taubenberger J, Reid A, Lourens R, Wang R, Guozhong J, Fanning T. (2005) Characterization of the 1918 influenza virus polymerase genes. Nature 437:889–893

    Article  CAS  PubMed  Google Scholar 

  • Treanor JJ, Wilkinson BE, Masseoud F et al. (2001) Safety and immunogenicity of a recombinant hemagglutinin vaccine for H5 influenza in humans. Vaccine 19:1732–1737

    Article  CAS  PubMed  Google Scholar 

  • Treanor JJ, Campbell James D, Zangwill KM, Rowe T, Wolff M. (2006) Safety and immunogenicity of an inactivated subvirion influenza A (H5N1) vaccine. N Engl J Med 354:1343–1351

    Article  CAS  PubMed  Google Scholar 

  • Treanor J, Bernstein D, Edwards K, Zangwill K, Noah D. (2007) Evaluation of inactivated monovalent rga/Vietnam/1203/04 X PR8 subvirion vaccine in healthy elderly adults. Abstract P731 of the Options for the Control of Influenza VI Meeting, Toronto, ON, Canada, 17–23 June 2007

    Google Scholar 

  • Vajo Z, Kosa L, IIdiko V, Jankovics M, Jankovics I. (2007) Inactivated whole virus influenza A (H5N1) vaccine. Emerg Infect Dis 13(5):807–808

    PubMed  Google Scholar 

  • Watanabe T, Watanabe S, Kim J, Hatta M, Kawaoka Y. (2008) Novel approach to the development of effective H5N1 influenza a virus vaccines: use of M2 cytoplasmic tail mutants. J Virol 82:5:2486–2492

    Article  CAS  PubMed  Google Scholar 

  • Wright PF, Thompson J, Vaughn WK, Folland DS, Sell SHW, Karzon DT. (1977) Trials of influenza A/New Jersey/76 virus-vaccine in normal children: overview of age-related antigenicity and reactogenicity. J Infect Dis 136:S731–S741

    PubMed  Google Scholar 

  • Writing Committee of the Second World Health Organization Consultation on Clinical Aspects of Human Infection with Avian Influenza A. (H5N1) Virus (2008) Update on avian influenza A (H5N1) virus infection in humans. N Engl J Med 358:261–273

    Article  Google Scholar 

  • Zangwill K, Treanor JJ, Campbell JD, Noah DL, Ryea J. (2008) Evaluation of the safety and immunogenicity of a booster (third) dose of inactivated subvirion H5N1 influenza vaccine in humans. J Infect Dis 197:580–583

    Article  PubMed  Google Scholar 

  • Zhou B, Zhong N, Guan Y. (2007) Treatment with convalescent plasma for influenza A(H5N1) infection. N Engl J Med 357:1450

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Molecular Virology & Microbiology and Medicine, Baylor College of Medicine, 280 One Baylor Plaza, Houston, TX, 77030, USA

    Wendy A. Keitel (Professor)

  2. Medicine and Molecular Virology & Microbiology, Baylor College of Medicine, 280 One Baylor Plaza, Houston, TX, 77030, USA

    Robert L. Atmar (Professor)

Authors
  1. Wendy A. Keitel
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Robert L. Atmar
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. School of Medicine, Emory University, Atlanta, 30322, U.S.A.

    Richard W. Compans

  2. School of Medicine, Emory University, Clifton Road 1510, Atlanta, 30322, U.S.A.

    Walter A. Orenstein

Rights and permissions

Reprints and permissions

Copyright information

© 2009 Springer-Verlag Berlin Heidelberg

About this chapter

Cite this chapter

Keitel, W.A., Atmar, R.L. (2009). Vaccines for Pandemic Influenza: Summary of Recent Clinical Trials. In: Compans, R., Orenstein, W. (eds) Vaccines for Pandemic Influenza. Current Topics in Microbiology and Immunology, vol 333. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-540-92165-3_21

Download citation

Publish with us

Policies and ethics

Search

Navigation